British scientists have developed a medicine in the form of pills to be taken by mouth, to treat diabetes.
The magazine “Scientific Report” that scientists at the University of British Columbia, were able to increase the speed of insulin absorption from tablets that must be placed between the gums and the buccal mucosa in the oral cavity.
Other options for using oral insulin tablets turned out to be less effective, because the hormone builds up in the stomach and does not reach the liver. Currently, insulin is released within 30-120 minutes instead of 2-4 hours.
The new drug consists of nanoparticles measuring 318 nanometers, containing insulin, chitosan and sodium tripolyphosphate, subjected to drying using hot gas, where the solid particles separate from the solvent. Insulin constitutes 25 percent of the material produced, with the efficiency of hormone absorption reaching 98-99 percent.
According to the researchers, this drug will improve the lives of millions of people with diabetes in the world, and they will not have to daily inject insulin into their body several times a day.
And the newspaper “Daily Mail” published the results of a study conducted by researchers from “Yale” University of America on the effectiveness of another drug for the treatment of diabetes patients in the fight once morest obesity and weight loss.
The study found that the drug “tirzepatide”, which has gained attention in recent years, can help an obese person lose weight by regarding 20 percent when taken weekly in addition to the usual diet and exercise.
The newspaper pointed out that the drug, “Terzipatide”, is currently only available by prescription and has only been approved by regulators for the treatment of diabetes. It is likely that the company “Eli Lilly” – which participated in the preparation of the study – to obtain approval for the use of “terizipatide” as a drug to lose weight as well.
This is the second study conducted by the company “Eli Lilly” in an attempt to prove that its drug can be useful in losing weight.
“This is an unusually large degree of weight loss in response to an anti-obesity drug compared to results reported in other Phase III clinical trials,” the researchers said, according to the paper.
